News

Standing up in public for a broader conception of value in healthcare.

9-16 of 60 News

viewpoint 6/02/17

On the Health Affairs Blog: Grabowski and Manning Respond To A Recent Post by Yu, Helms, and Bach Henry Grabowski and Richard Manning offer a rebuttal to a recent Health Affairs blog post by authors Yu, Helms, and Bach on the subject of drug pricing, arguing the authors’ premise is flawed and suffers from numerous biases and related methodological issues. READ MORE

viewpoint 6/01/17

On the Health Affairs Blog: Carrier and Shadowen Propose Fixes for Pharma "Product Hopping" Michael Carrier and Steve Shadower present the issue of "product hopping," in which pharma manufacturers can delay the generic introduction of a drug through reformulation. In addition to examining the issue, Carrier and Shadowen propose some criteria for the development of a new framework to address abuses in this practice. READ MORE

viewpoint 5/26/17

On the Health Affairs Blog: Manolis, Good and Shrank Address Abuse-Deterrent Opioids Chronis Manolis, C Bernie Good and William Shrank discuss current approaches to curb opioid abuse, including the proposal to mandate coverage of abuse-deterrent opioids. READ MORE

viewpoint 5/23/17

On the Health Affairs Blog: What Matters Most To Patients Josh Seidman, Margaret Anderson, Domitilla Masi, Melea Atkins and Maureen Japha provide an overview of the Avalere-FasterCures Patient-Perspective Value Framework. READ MORE

viewpoint 5/18/17

On the Health Affairs Blog: Seabury and Sood Examine Policies to Promote Development of Antimicrobial Drugs Seth Seabury and Neeraj Sood propose a new model for the development of antimicrobial drugs. Market entry awards, exclusivity extensions and priority review vouchers are all critical tools that the authors examine, weighing their strengths and weaknesses. READ MORE

viewpoint 5/15/17

On the Health Affairs Blog: Sachs Reviews Key Provisions of FDA's User Fee Reauthorization Bill Rachel Sachs provides an update of the progress of the new FDA user fee reauthorization bill and its key provisions. Sachs outlines the revisions to the law and overall goals, as well as other possible obstacles to the bill's passage in the near future. READ MORE

viewpoint 5/12/17

On the Health Affairs Blog: Hwang and Kesselheim Analyze the Impact of Taxing Drug Price Spikes Thomas Hwang and Aaron Kesselheim focus on recent efforts to establish an excise tax on drugs with significant price increases as a means of lowering drug costs and improving transparency. READ MORE

viewpoint 5/09/17

On the Health Affairs Blog: Lakdawalla and Balch Make the Case for Patient-Centered Assessment of Value IVI's Darius Lakdawalla and Alan Balch stress the need to begin actively incorporating the patient perspective into the measures used to assess value in healthcare. READ MORE